Waukesha-based Cardiac Science Corp. announced today that its board of directors has appointed Devdatt “Dev” Kurdikar as chief executive officer.
“The board is excited to announce Dev’s appointment as CEO to lead Cardiac Science through the next phase of its growth,” said Sean Ozbolt, chairman of Cardiac Science’s board of directors. “Dev is a highly accomplished health care executive with an outstanding track record of success, and his experience leading global operations for major medical device businesses will be a tremendous asset to Cardiac Science. We look forward to a long, productive partnership with Dev and the exceptionally strong leadership team at Cardiac Science.”
Kurdikar has more than 20 years of experience in the life sciences and health care industry. He spent the last three years as the general manager of the Men’s Health business of Boston Scientific and that business’s predecessor at American Medical Systems (AMS). Prior to AMS, Dev spent 11 years at Baxter Corp. in various leadership positions across several areas including strategy and operations, product development, finance, and marketing.
“I am honored to be appointed CEO of this world-class organization, and I am excited about the opportunity to help lead the continued resurgence of Cardiac Science,” Kurdikar said.
Cardiac Science is a defibrillator manufacturer, which is owned by Los Angeles-based private equity firm Aurora Resurgence.
“For over 25 years, this company has played a critical role in saving victims of sudden cardiac arrest around the world, and we will continue to support this mission as we expand our product lines and global presence,” Kurdikar said. “Today, Cardiac Science is growing meaningfully and there is an extraordinary passion to win at every level of the organization, and I look forward to working with this impressive team to build on the company’s success.”
